Full Title
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Daniel Danila’s office at 646-422-4612.
Protocol
26-313
Phase
Phase III (phase 3)
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07213674
ClinicalTrials.gov